Citryll
Phase 2Citryll is pioneering treatments for immune-mediated inflammatory diseases targeting Neutrophil Extracellular Traps with CIT-013.
Founded
2015
Focus
AntibodiesBiologics
About
Citryll is pioneering treatments for immune-mediated inflammatory diseases targeting Neutrophil Extracellular Traps with CIT-013.
Funding History
3Total raised: $53M
Series B$30MYsios CapitalSep 15, 2022
Series A$20MBioGeneration VenturesMar 15, 2020
Seed$3MBioGeneration VenturesMay 15, 2018
Company Info
TypePrivate
Founded2015
LocationOss, Netherlands
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile